Nalaganje...
Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
PURPOSE: Evolocumab significantly reduces low-density lipoprotein-cholesterol (LDL-C); we investigated its effects on LDL-C lowering in patients with mixed hyperlipidemia. METHODS: We compared the efficacy and safety of evolocumab in hypercholesterolemic patients selected from the phase 2 and 3 tria...
Shranjeno v:
| izdano v: | Cardiovasc Drugs Ther |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Springer US
2016
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4919379/ https://ncbi.nlm.nih.gov/pubmed/27240673 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10557-016-6666-1 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|